CPK850 / Novartis - LARVOL DELTA

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=12 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=15 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

First-in-human • New P1/2 trial • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=21 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial completion date: May 2025 ➔ Sep 2025 | Trial primary completion date: May 2025 ➔ Sep 2025

Enrollment open • First-in-human • Trial completion date • Trial primary completion date • Gene Therapies • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=21 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | N=15 ➔ 21

Enrollment change • First-in-human • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2027 ➔ May 2026 | Trial primary completion date: Aug 2027 ➔ May 2026

First-in-human • Trial completion date • Trial primary completion date • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=21 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Nov 2025 ➔ Jul 2026 | Trial primary completion date: Nov 2025 ➔ Jul 2026

First-in-human • Trial completion date • Trial primary completion date • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=12 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • First-in-human • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jul 2026 ➔ Jan 2027 | Trial primary completion date: Jul 2026 ➔ Jan 2027

First-in-human • Trial completion date • Trial primary completion date • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

CCPK850X2202: A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=15 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jan 2027 ➔ Aug 2027 | Trial primary completion date: Jan 2027 ➔ Aug 2027

First-in-human • Trial completion date • Trial primary completion date • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

"$NVS is also seeking to partner out CPK850 (RLBP 1 gene therapy for retinitis pigmentosa) & CSJ117 (anti-TSLP MAb for asthma)" (,@JacobPlieth)

Asthma • Gene Therapies • Genetic Disorders • Immunology • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Retinal Disorders • Retinitis Pigmentosa